Pancragen
Also known as: Pancreatic bioregulator, Lys-Glu-Asp-Trp
Pancragen (also called Pancreatic bioregulator or Lys-Glu-Asp-Trp) is a khavinson pancreatic bioregulator. Pancragen is Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson series associated with pancreatic tissue. Following the series hypothesis, it is proposed to reach the cell nucleus and interact with specific DNA promoter regions to influence transcription of genes governing pancreatic cell function, with reported effects on carbohydrate metabolism markers in animal models.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Pancreatic cells (proposed)
Research summary
Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson bioregulator series associated with pancreatic tissue, with reported effects on carbohydrate metabolism markers in animal models. It should not be confused with Suprefort, the tissue extract marketed for the same organ. The supporting literature is regional and uncontrolled, and it is not FDA-approved or a treatment for diabetes.
Peptide Library's Pancragen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pancragen is Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson series associated with pancreatic tissue. Following the series hypothesis, it is proposed to reach the cell nucleus and interact with specific DNA promoter regions to influence transcription of genes governing pancreatic cell function, with reported effects on carbohydrate metabolism markers in animal models. As with the rest of the series the supporting literature comes predominantly from one research group and is published in Russian-language journals; there is no independent replication, no identified receptor, and no controlled human evidence.
Origin
Synthetic short peptide.
Targets
Studies
- [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys]
- [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]
- Effects of pancragen on the differentiation of pancreatic cells during their ageing
- Prospects of using pancragen for correction of metabolic disorders in elderly people
- Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide
Regulatory & research status
Pancragen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pancragen: frequently asked questions
What is Pancragen?
Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson bioregulator series associated with pancreatic tissue, with reported effects on carbohydrate metabolism markers in animal models. It should not be confused with Suprefort, the tissue extract marketed for the same organ. The supporting literature is regional and uncontrolled, and it is not FDA-approved or a treatment for diabetes.
How does Pancragen work?
Pancragen is Lys-Glu-Asp-Trp, a synthetic tetrapeptide in the Khavinson series associated with pancreatic tissue. Following the series hypothesis, it is proposed to reach the cell nucleus and interact with specific DNA promoter regions to influence transcription of genes governing pancreatic cell function, with reported effects on carbohydrate metabolism markers in animal models.
Is Pancragen FDA approved?
No. Pancragen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Pancragen?
Compounds most often compared with Pancragen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys] — Adv Gerontol, 2015External reference
- [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys] — Adv Gerontol, 2014External reference
- Effects of pancragen on the differentiation of pancreatic cells during their ageing — Bull Exp Biol Med, 2013External reference
- Prospects of using pancragen for correction of metabolic disorders in elderly people — Bull Exp Biol Med, 2011External reference
- Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide — Bull Exp Biol Med, 2010External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Pancragen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pancragen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →